Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Net Income towards Common Stockholders (2016 - 2026)

Corcept Therapeutics' Net Income towards Common Stockholders history spans 16 years, with the latest figure at -$31.2 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 253.8% to -$31.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $46.7 million, a 64.77% decrease, with the full-year FY2025 number at $98.2 million, down 29.74% from a year prior.
  • Net Income towards Common Stockholders hit -$31.2 million in Q1 2026 for Corcept Therapeutics, down from $23.9 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for CORT hit a ceiling of $46.7 million in Q3 2024 and a floor of -$31.2 million in Q1 2026.
  • Historically, Net Income towards Common Stockholders has averaged $24.3 million across 5 years, with a median of $27.4 million in 2022.
  • Biggest five-year swings in Net Income towards Common Stockholders: soared 88.37% in 2023 and later crashed 253.8% in 2026.
  • Tracing CORT's Net Income towards Common Stockholders over 5 years: stood at $16.5 million in 2022, then soared by 88.37% to $31.1 million in 2023, then fell by 2.42% to $30.4 million in 2024, then fell by 21.34% to $23.9 million in 2025, then tumbled by 230.53% to -$31.2 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for CORT at -$31.2 million in Q1 2026, $23.9 million in Q4 2025, and $19.4 million in Q3 2025.